Prexa Pharmaceuticals' Series B Round

Prexa Pharmaceuticals raised a round of funding on April 30, 2011. Investors include Synthesis Capital.

Prexa Pharmaceuticals develops product candidates designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as…

Articles about Prexa Pharmaceuticals' Series B Round: